NZ597563A - Muc1 antibodies - Google Patents
Muc1 antibodiesInfo
- Publication number
- NZ597563A NZ597563A NZ597563A NZ59756310A NZ597563A NZ 597563 A NZ597563 A NZ 597563A NZ 597563 A NZ597563 A NZ 597563A NZ 59756310 A NZ59756310 A NZ 59756310A NZ 597563 A NZ597563 A NZ 597563A
- Authority
- NZ
- New Zealand
- Prior art keywords
- chain variable
- variable region
- antibody
- disclosed
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23021109P | 2009-07-31 | 2009-07-31 | |
| EP09009942A EP2281844A1 (en) | 2009-07-31 | 2009-07-31 | MUC 1 antibodies |
| PCT/EP2010/004663 WO2011012309A1 (en) | 2009-07-31 | 2010-07-30 | Muc1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ597563A true NZ597563A (en) | 2013-08-30 |
Family
ID=41460131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ597563A NZ597563A (en) | 2009-07-31 | 2010-07-30 | Muc1 antibodies |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9217038B2 (enExample) |
| EP (3) | EP2281844A1 (enExample) |
| JP (2) | JP5922018B2 (enExample) |
| KR (1) | KR101773506B1 (enExample) |
| CN (1) | CN102574926B (enExample) |
| AR (1) | AR077334A1 (enExample) |
| AU (1) | AU2010278302B2 (enExample) |
| BR (1) | BR112012002226A2 (enExample) |
| CA (1) | CA2768888C (enExample) |
| CU (1) | CU23972B1 (enExample) |
| EA (1) | EA029954B1 (enExample) |
| IL (1) | IL217827A (enExample) |
| MX (1) | MX2012000874A (enExample) |
| NZ (1) | NZ597563A (enExample) |
| SG (2) | SG10201404019XA (enExample) |
| WO (1) | WO2011012309A1 (enExample) |
| ZA (1) | ZA201200166B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3539981A1 (en) | 2006-09-10 | 2019-09-18 | Glycotope GmbH | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| PL1920781T3 (pl) * | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| PT2603528T (pt) | 2010-08-10 | 2016-12-01 | Glycotope Gmbh | Anticorpos glicosilados em fab |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| ES2686313T3 (es) | 2011-08-22 | 2018-10-17 | Glycotope Gmbh | Microorganismos que portan un antígeno tumoral |
| CN103848890B (zh) * | 2012-11-30 | 2015-09-09 | 北京市结核病胸部肿瘤研究所 | Muc1自身抗体识别的抗原多肽 |
| EP2963126B1 (en) * | 2013-03-01 | 2019-04-03 | Saitama Medical University | Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting muc4 gene polymorphism |
| US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| CA2938819A1 (en) | 2014-02-06 | 2015-08-13 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Antibody to mucin 4 (muc4) glycopeptide and uses thereof |
| US10239950B2 (en) * | 2014-04-28 | 2019-03-26 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof |
| WO2016026143A1 (en) * | 2014-08-22 | 2016-02-25 | Huiru Wang | Saccharide-based biomarkers and therapeutics |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| CN116199790A (zh) | 2015-02-10 | 2023-06-02 | 米纳瓦生物技术公司 | 人源化抗MUCl*抗体 |
| WO2017139975A1 (en) | 2016-02-19 | 2017-08-24 | Huiru Wang | Antibodies against n-acetylglucosamine and n-acetyl-galactosamine |
| TWI780082B (zh) | 2016-11-18 | 2022-10-11 | 日商安斯泰來製藥股份有限公司 | 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段 |
| EP3570881A4 (en) * | 2017-01-18 | 2020-08-19 | Nanocruise Pharmaceutical Ltd. | MONOCLONAL AND HUMANIZED ANTIBODIES DIRECTED AGAINST CANCER GLYCOPEPTIDE |
| US20190343953A1 (en) | 2017-01-27 | 2019-11-14 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| WO2018178047A1 (en) | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Multispecific antibody constructs binding to muc1 and cd3 |
| WO2018178046A1 (en) | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Humanized anti-cd40 antibodies |
| US20200148785A1 (en) * | 2017-03-29 | 2020-05-14 | Glycotope (GmbH) | Pd-l1 and ta-muc1 antibodies |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| NZ762505A (en) | 2017-09-29 | 2026-03-27 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US12605469B2 (en) | 2017-10-02 | 2026-04-21 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| US11161911B2 (en) | 2017-10-23 | 2021-11-02 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
| BR112020008001A2 (pt) * | 2017-10-24 | 2020-10-20 | Go Therapeutics, Inc. | anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica. |
| CA3090407A1 (en) * | 2018-03-01 | 2019-09-06 | Glycotope Gmbh | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
| BR112020023420A8 (pt) | 2018-05-17 | 2022-07-05 | Astellas Pharma Inc | Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante |
| SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
| CN108982854B (zh) * | 2018-06-19 | 2021-07-27 | 哈尔滨医科大学 | 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用 |
| JP7541930B2 (ja) * | 2018-06-29 | 2024-08-29 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｍｕｃ１抗体およびその使用 |
| SG11202103670XA (en) | 2018-10-10 | 2021-05-28 | Astellas Pharma Inc | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| CN113631229B (zh) | 2019-03-25 | 2025-09-23 | 第一三共株式会社 | 抗体－吡咯并苯并二氮杂卓衍生物偶联物 |
| CA3139180A1 (en) | 2019-03-27 | 2020-10-01 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
| WO2023121448A1 (en) * | 2021-12-21 | 2023-06-29 | Merus N.V. | Binding domains against cancer-associated muc1 |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| TW202506190A (zh) | 2023-04-05 | 2025-02-16 | 日商第一三共股份有限公司 | 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5683674A (en) | 1987-01-07 | 1997-11-04 | Imperial Cancer Research Technology Ltd. | Antibody against human mucin core protein and method of preparing and using same |
| JP3698370B2 (ja) | 1992-04-13 | 2005-09-21 | ダナ−ファーバー キャンサー インスティチュート インク | 癌腫抗原用抗体 |
| US5804187A (en) | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6465220B1 (en) * | 1998-12-21 | 2002-10-15 | Glycozym Aps | Glycosylation using GalNac-T4 transferase |
| US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| ATE290879T1 (de) | 1999-08-18 | 2005-04-15 | Altarex Medical Corp | Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung |
| GB0029360D0 (en) | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
| ES2524442T3 (es) | 2002-07-22 | 2014-12-09 | Glycotope Gmbh | Procedimiento para la producción de una mucina (MUC1) inmunoestimulante |
| DK1530628T3 (da) | 2002-08-16 | 2011-01-10 | Glycotope Gmbh | Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| SI1654353T1 (sl) | 2003-08-18 | 2013-09-30 | Glycotope Gmbh | Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe |
| CN103627670B (zh) | 2004-02-13 | 2016-12-21 | 格莱克托普有限公司 | 高活性糖蛋白加工条件及其有效生产方法 |
| EP3539981A1 (en) | 2006-09-10 | 2019-09-18 | Glycotope GmbH | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
-
2009
- 2009-07-31 EP EP09009942A patent/EP2281844A1/en not_active Withdrawn
-
2010
- 2010-07-28 AR ARP100102737A patent/AR077334A1/es not_active Application Discontinuation
- 2010-07-30 NZ NZ597563A patent/NZ597563A/xx unknown
- 2010-07-30 WO PCT/EP2010/004663 patent/WO2011012309A1/en not_active Ceased
- 2010-07-30 MX MX2012000874A patent/MX2012000874A/es active IP Right Grant
- 2010-07-30 CA CA2768888A patent/CA2768888C/en active Active
- 2010-07-30 US US13/387,587 patent/US9217038B2/en active Active
- 2010-07-30 EP EP18181262.9A patent/EP3421497A1/en not_active Withdrawn
- 2010-07-30 BR BR112012002226A patent/BR112012002226A2/pt not_active Application Discontinuation
- 2010-07-30 CN CN201080033969.9A patent/CN102574926B/zh active Active
- 2010-07-30 SG SG10201404019XA patent/SG10201404019XA/en unknown
- 2010-07-30 SG SG2012000865A patent/SG177527A1/en unknown
- 2010-07-30 EP EP10746999A patent/EP2459595A1/en not_active Withdrawn
- 2010-07-30 EA EA201270207A patent/EA029954B1/ru unknown
- 2010-07-30 AU AU2010278302A patent/AU2010278302B2/en active Active
- 2010-07-30 KR KR1020127005121A patent/KR101773506B1/ko active Active
- 2010-07-30 JP JP2012522029A patent/JP5922018B2/ja active Active
-
2012
- 2012-01-09 ZA ZA2012/00166A patent/ZA201200166B/en unknown
- 2012-01-30 IL IL217827A patent/IL217827A/en active IP Right Grant
- 2012-01-30 CU CU2012000019A patent/CU23972B1/es active IP Right Grant
-
2016
- 2016-01-04 JP JP2016000133A patent/JP6272916B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010278302B2 (en) | 2014-12-18 |
| SG10201404019XA (en) | 2014-09-26 |
| CU23972B1 (es) | 2013-12-27 |
| WO2011012309A8 (en) | 2011-04-07 |
| AR077334A1 (es) | 2011-08-17 |
| KR20120051724A (ko) | 2012-05-22 |
| ZA201200166B (en) | 2013-03-27 |
| JP6272916B2 (ja) | 2018-01-31 |
| CA2768888A1 (en) | 2011-02-03 |
| CN102574926A (zh) | 2012-07-11 |
| CN102574926B (zh) | 2014-10-15 |
| US9217038B2 (en) | 2015-12-22 |
| IL217827A0 (en) | 2012-03-29 |
| BR112012002226A2 (pt) | 2016-11-08 |
| CU20120019A7 (es) | 2012-06-21 |
| AU2010278302A1 (en) | 2012-02-09 |
| EA029954B1 (ru) | 2018-06-29 |
| US20120128676A1 (en) | 2012-05-24 |
| JP5922018B2 (ja) | 2016-05-24 |
| SG177527A1 (en) | 2012-02-28 |
| EP2281844A1 (en) | 2011-02-09 |
| CA2768888C (en) | 2019-02-26 |
| MX2012000874A (es) | 2012-02-01 |
| EA201270207A1 (ru) | 2012-07-30 |
| EP2459595A1 (en) | 2012-06-06 |
| WO2011012309A1 (en) | 2011-02-03 |
| IL217827A (en) | 2017-05-29 |
| JP2013500703A (ja) | 2013-01-10 |
| EP3421497A1 (en) | 2019-01-02 |
| KR101773506B1 (ko) | 2017-08-31 |
| JP2016041771A (ja) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ597563A (en) | Muc1 antibodies | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| WO2009048537A3 (en) | Humanized antibody | |
| NZ599140A (en) | Antibodies that specifically bind to the epha2 receptor | |
| WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| WO2009048539A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| PH12016500658B1 (en) | Human anti-alpha-synuclein autoantibodies | |
| NZ717847A (en) | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof | |
| EA200970694A1 (ru) | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ | |
| MX357193B (es) | Moleculas de union anti-alfa sinucleina. | |
| EA201290173A1 (ru) | Антитела против эндоглина | |
| MX2018008680A (es) | Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43). | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| IL186948A0 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
| PE20120622A1 (es) | Anticuerpos anti-vegf y sus usos | |
| GB201005064D0 (en) | Biological products | |
| MX2015003150A (es) | Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos. | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| NZ597611A (en) | Anti notch-1 antibodies | |
| MX340350B (es) | Proteinas de union a antigeno especificas para el componente p amiloide serico. | |
| MX2009008754A (es) | Anticuerpos novedosos contra igf-1r. | |
| UA108207C2 (xx) | Високоафінне людське антитіло до людського ангіопоетину-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 JUL 2017 BY PAVIS EG Effective date: 20140724 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2018 BY PAVIS GMBH Effective date: 20170721 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2019 BY PAVIS GMBH Effective date: 20180720 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2020 BY PAVIS GMBH Effective date: 20190717 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2021 BY PAVIS PAYMENTS GMBH Effective date: 20200724 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2022 BY PAVIS PAYMENTS GMBH Effective date: 20210721 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2023 BY PAVIS PAYMENTS GMBH Effective date: 20220720 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2024 BY PAVIS PAYMENTS GMBH Effective date: 20230718 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2025 BY PAVIS PAYMENTS GMBH Effective date: 20240715 |
|
| ASS | Change of ownership |
Owner name: DAIICHI SANKYO COMPANY, JP Effective date: 20250507 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2026 BY PAVIS PAYMENT GMBH Effective date: 20250718 |